55
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Drugs for bad bugs: confronting the challenges of antibacterial discovery.

      Nature reviews. Drug discovery

      Animals, Anti-Bacterial Agents, therapeutic use, Bacteria, drug effects, genetics, Bacterial Infections, drug therapy, microbiology, Drug Design, Genomics, Humans

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets. Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action. Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.

          Related collections

          Author and article information

          Journal
          17159923
          10.1038/nrd2201

          Comments

          Comment on this article